ASF -survivors’ sera do not inhibit African swine fever virus replication in vitro
Data publikacji: 25 mar 2022
Zakres stron: 21 - 27
Otrzymano: 22 gru 2021
Przyjęty: 08 mar 2022
DOI: https://doi.org/10.2478/jvetres-2022-0016
Słowa kluczowe
© 2022 M. Walczak et al. published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Introduction
African swine fever virus (ASFV) causes one of the most dangerous diseases of pigs and wild boar – African swine fever (ASF). Since its second introduction into Europe (in 2007), the disease has been spreading consistently, and now ASF-free European countries are at risk. Complex interactions between the host’s immune system and the virus have long prevented the development of a safe vaccine against ASF. This study analysed the possibility of neutralisation of the ASFV
Material and Methods
Two pig and three wild boar serum samples were collected from previously selected potential ASF survivors. All sera presented high antibody titres (>5 log10/mL). Primary alveolar macrophages were cultured in growth medium containing 10% and 20% concentrations of selected sera and infected with a haemadsorbing ASFV strain (Pol18_28298_O111, genotype II). The progress of infection was investigated under a light microscope by observing the cytopathic effect (CPE) and the haemadsorption phenomenon. Growth kinetics were investigated using a real-time PCR assay.
Results
Haemadsorption inhibition was detected in the presence of almost all selected sera; however, the inhibition of virus replication
Conclusion
Anti-ASFV antibodies alone are not able to inhibit virus replication. Interactions between the humoral and cellular immune response which effectively combat the disease are implicated in an ASF-survivor’s organism.